- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Cue Biopharma (CUE)Cue Biopharma stock price live, this page displays NASDAQ CUE stock exchange data. View the CUE premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Cue Biopharma real time stock price chart below.
What Is the Cue Biopharma Stock Price Today?
The Cue Biopharma stock price today is 1.100.
What Is the Stock Symbol for Cue Biopharma?
The stock symbol for Cue Biopharma is "CUE."
What Stock Exchange Does Cue Biopharma Trade On?
Cue Biopharma is listed and trades on the NASDAQ stock exchange.
Is Cue Biopharma a Good Stock to Buy?
Determining whether Cue Biopharma—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CUE quote. (ISIN: US22978P1066)
What Is the Cue Biopharma Stock Price Today?
The Cue Biopharma stock price today is 1.100.
What Is the Stock Symbol for Cue Biopharma?
The stock symbol for Cue Biopharma is "CUE."
What Stock Exchange Does Cue Biopharma Trade On?
Cue Biopharma is listed and trades on the NASDAQ stock exchange.
Is Cue Biopharma a Good Stock to Buy?
Determining whether Cue Biopharma—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CUE quote. (ISIN: US22978P1066)
1.100
+0.050(+4.76%)
Closed
After Hours
1.110+0.010(+0.909%)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.020
1.110
52 wk Range
0.450
3.200
CUE Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.0201.110
52 wk Range
0.4503.200
Key Statistics
Edit
Book Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
UnlockN/A
(N/A)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockBook Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
UnlockN/A
(N/A)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockCUE Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
3.600
Upside
+227.273%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Cue Biopharma Company Profile
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient’s body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms’ Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Cue Biopharma SWOT Analysis
Strategic Pivot | Cue Biopharma shifts focus to autoimmune diseases, restructuring operations and advancing novel biologic therapies like the CUE-500 series for off-the-shelf treatments |
Clinical Milestones | Explore Cue Biopharma's oncology progress, including positive Phase II results for CUE-101 in HNSCC and ongoing trials for CUE-102 in WT1+ solid tumors |
Financial Outlook | Learn about Cue Biopharma's $41 million cash position, extended runway to mid-2025, and potential for additional partnerships to boost development programs |
Market Positioning | Delve into Cue Biopharma's competitive stance in autoimmune and oncology sectors, with analyst price targets ranging from $2 to $15 per share |
CUE Full Pro Research
Institutional-Grade Stock Analysis
Understand how CUE earns money
Financial health at a glance
Bearish and bullish outlooks
Latest expert insights
Actionable Pro Tips, and many more...
Gain access to 1400+ in-depth research reports on the most popular US stocks
Cue Biopharma Earnings Call Summary for Q2/2024
- CUE-101 and CUE-102 show promise in cancer treatment, with CUE-101 advancing to Phase 2 study for HPV+ head and neck cancer
- Collaboration revenue of $1.8M for Q4 2023, primarily from Ono Pharmaceuticals partnership; $48.5M cash on hand as of Dec 31, 2023
- Company seeks strategic partnerships to enhance development capacity and capital access for oncology and autoimmune programs
- CUE-401 and CUE-500 series demonstrate potential in restoring immune balance for autoimmune diseases
- Data presentations scheduled for ASCO, including longer follow-up and results from ~35 patients in CUE-101-01 and CUE-102 trials
Last Updated: 10/04/2024, 06:36 am
Read Full TranscriptCompare CUE to Peers and Sector
Metrics to compare | CUE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCUEPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.6x | −1.6x | −0.6x | |
PEG Ratio | −0.06 | 0.03 | 0.00 | |
Price/Book | 2.7x | 1.4x | 2.6x | |
Price / LTM Sales | 7.3x | 13.3x | 3.2x | |
Upside (Analyst Target) | 263.6% | 327.3% | 44.6% | |
Fair Value Upside | Unlock | 8.5% | 7.3% | Unlock |
Analysts' Recommendations
5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 3.600
(+227.27% Upside)
People Also Watch
FAQ
What Is the Cue Biopharma (CUE) Stock Price Today?
The Cue Biopharma stock price today is 1.10
What Stock Exchange Does Cue Biopharma Trade On?
Cue Biopharma is listed and trades on the NASDAQ stock exchange.
What Is the Stock Symbol for Cue Biopharma?
The stock symbol for Cue Biopharma is "CUE."
What Is the Cue Biopharma Market Cap?
As of today, Cue Biopharma market cap is 69.69M.
What is Cue Biopharma Earnings Per Share?
The Cue Biopharma EPS is -0.901.
What Is the Next Cue Biopharma Earnings Date?
Cue Biopharma will release its next earnings report on 11 Mar 2025.
From a Technical Analysis Perspective, Is CUE a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.